true 2008-03-01 <h2>The Cystic Fibrosis Foundation’s Indiana Chapter received an award for outstanding fund-raising efficiency during the organization’s annual Volunteer Leadership Initiative Meeting. Nearly 300 people from across the country attended the event, held in our nation’s capital.</h2> <p>The award lauds the Indiana Chapter as a top fund-raising office, and specifically recognizes the enduring success of Guys and Dolls; an event that unites Indiana’s young professionals in the fight against cystic fibrosis.</p> <p>Jim Woods, the foundation’s Director of Field Management and Recruitment, explains that the Indiana Chapter richly deserved the award because Guys and Dolls, now in its 20th year is considered a "mature" event with a great committee. There is much buzz about this young professional event that the committee interviews new prospective committee members to make sure they are committed to achieving the Foundation's goals. While the volunteer committee operates like a business, they know how to have fun - all of this has led Indiana Guys and Dolls event to the top - raising $215,000 this past year!”</p> <p>The Cystic Fibrosis Foundation is one of the most efficient organizations of its kind, with nearly 90 percent of every dollar of revenue raised available for investment in research, care and education programs. Today, the predicted median age of survival for people with cystic fibrosis is 37 years-more than double what it was 25 years ago.</p> <p>For further information about Guys and Dolls, contact Liz Fraim, Special Events Director at 317-202-9210.</p> 2008-05-08T00:55:55-05:00 2008-05-08 1 1 2008-05-08 2008-05-08T00:55:55-05:00 false 2008-03-27 <p>The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.</p> <p>Patients who took the drug for 14 days showed significant improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels. The findings suggest that VX-770 improves function of what is known as the faulty CFTR protein. This early data is promising and could have important implications for studies of other drugs in development.</p> <p>This is the first time that any potential therapy has improved the abnormal sweat chloride (salt) levels in a person with CF. Excessive sweat chloride is a key clinical indicator of cystic fibrosis. The “sweat test” is the traditional diagnostic test for CF.</p> <p>"These early results are an extraordinary endorsement of our hypothesis—that small molecules can correct the basic defect and affect the clinical indicators of cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the Foundation. "The emerging data for VX-770 represents the most exciting results we’ve seen from a Phase 2 trial and increase our confidence that we’re on the right track."</p> 2008-05-08T01:17:55-05:00 2008-05-08 3 2008-05-08 2008-05-08T01:17:55-05:00 true 2008-04-29 <p>The Cystic Fibrosis Foundation praised the U.S. Senate for officially recognizing May as National Cystic Fibrosis Awareness Month and encouraging public awareness and understanding of CF.</p> <p>Introduced by Senators Patty Murray (D-Wash.) and Jim Inhofe (R-Okla.), the legislation calls attention to cystic fibrosis, a fatal, genetic disease, and supports research to find a cure.</p> <p>"We are thrilled to have the Senate’s support for our mission to find a cure for cystic fibrosis. We are making dramatic progress in the development of new therapies for the disease and in extending life expectancy," said Robert J. Beall, Ph.D., president and CEO of the Foundation. "On behalf of all those affected by CF, we thank Senators Murray and Inhofe for their leadership and commitment to the cystic fibrosis community.""</p> 2008-05-08T01:19:51-05:00 2008-05-08 4 2008-05-08 2008-05-08T01:19:51-05:00 true 2008-03-20 <div style="float:right"><img src="http://www.cff.org/UploadedImages/ImageGallery/4starrect.jpg"/></div><p>The Cystic Fibrosis Foundation announced today it has received a coveted 4-star rating for sound fiscal management from Charity Navigator, the largest charity evaluator in the United States.</p> <p>The Foundation earned four out of four possible stars for achieving excellence in fiscal responsibility. With this top rating, the Foundation outperforms a majority of nonprofits in America with respect to fiscal management, according to Charity Navigator. <a href="http://www.charitynavigator.org/index.cfm?bay=search.summary&orgid=9142">Click here to read about the Foundation’s 4-star rating</a>.</p> <p>"The Cystic Fibrosis Foundation understands that it is the custodian of the public’s trust with respect to every dollar donated to fight cystic fibrosis," said C. Richard Mattingly, executive vice president and chief operating officer of the Cystic Fibrosis Foundation. "We greatly value the coveted 4-star rating. It speaks directly to the effective and efficient way the Foundation manages its finances."</p> <p>In fact, 90 cents on the dollar raised by the Foundation is available to fund research, care and education programs for CF.</p> 2008-05-08T01:25:44-05:00 2008-05-08 5 2008-05-08 2008-05-08T01:25:44-05:00